UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Patient Information Leaflet last updated on the eMC: 17/05/2011
PIL Vimpat 50 mg, 100 mg, 150 mg & 200 mg film-coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 05/05/2011 and displayed until 17/05/2011
Reasons for adding or updating:
  • Change of inactive ingredient
  • Change to Further Information section
  • Change to warnings or special precautions for use
Updated on 07/12/2010 and displayed until 05/05/2011
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 25/05/2010 and displayed until 07/12/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 18/02/2010 and displayed until 25/05/2010
Reasons for adding or updating:
  • Change to date of revision
  • Correction of spelling/typing errors
Updated on 12/09/2008 and displayed until 18/02/2010
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   lacosamide